Purple Biotech
PPBT
6 hedge funds and large institutions have $225K invested in Purple Biotech in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
20% more funds holding
Funds holding: 5 → 6 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
7% less capital invested
Capital invested by funds: $242K → $225K (-$17K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Menta Capital
San Francisco,
California
|
+$111K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$63.3K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$55.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$87K |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$47K |
| 3 |
VF
Virtu Financial
New York
|
-$31K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.95K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MC
1
Menta Capital
San Francisco,
California
| $97K | +$111K | +28 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $57K | +$63.3K | +16 | New |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| $47K | +$55.4K | +14 | New |
|
4
Wells Fargo
San Francisco,
California
| $17K | – | – | – |
|
|
5
Morgan Stanley
New York
| $5K | -$87K | -22 | -92% |
|
|
6
UBS Group
Zurich,
Switzerland
| $2K | -$3.95K | -1 | -50% |
|
|
EIM
7
Essex Investment Management
Boston,
Massachusetts
| – | -$47K | -9 | Closed |
|
|
VF
8
Virtu Financial
New York
| – | -$31K | -6 | Closed |
|
PPBT Hedge Fund Activity: Q3 2018 in Review
6 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q3 2018, worth a combined $225K — down 7% from $242K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PPBT positions and 2 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Menta Capital, opening a new position worth an estimated $111K. The largest seller was Morgan Stanley, cutting an estimated $87K.
- 6 institutional investors held Purple Biotech (PPBT) as of Q3 2018, up from 5 in Q2 2018.
- Funds reported $225K of Purple Biotech stock for Q3 2018, down 7% quarter-over-quarter.
- 3 funds opened new Purple Biotech positions in Q3 2018 and 2 closed out, a net change of +1 holder.
- The largest Purple Biotech buyer in Q3 2018 was Menta Capital, an estimated $111K added.
- The largest Purple Biotech seller in Q3 2018 was Morgan Stanley, an estimated $87K sold.
Based on aggregated 13F filings for Q3 2018.